Pharmaceutical composition capable of resisting chronic infection and biofilm bacteria and use thereof
A composition and biofilm technology, applied in the field of medicine, can solve the problems of poor activity of non-growing persistent bacteria and limited therapeutic effect, and achieve the effects of wide application range, clearing infection and alleviating inflammation
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0051] In the existing technology, vancomycin is usually used for the treatment of infection. Although vancomycin is very effective in killing methicillin-resistant Staphylococcus aureus in vitro, in terms of clearing chronic Staphylococcus aureus infection, vancomycin is single Treatment may not be the most effective. At least 6 weeks if vancomycin is used as monotherapy or drug combination therapy; up to 10 days if combination therapy is used, such as combination of doxycycline and rifampicin; combination of vancomycin, gentamicin and Rifampicin, treated for at least 6 weeks, combined drug can also be used to treat chronic infection, exemplarily, it is used to treat conditions such as osteomyelitis and artificial joint infection.
[0052] In this experiment, four groups of different drugs were used for treatment, and the effect of the drugs was verified by experiments. Among them, no drug (i.e., blank none) was used as the first group of experiments, and vancomycin (Vancomyc...
Embodiment 2
[0055] Biofilms of S. aureus strain USA300, a common circulating strain of methicillin-resistant S. aureus (CA-MRSA), were grown on 96-well plates (achieved by microtiter plate biofilms). In order to determine an effective combination, the present invention has tested multiple drug combinations in an in vitro biofilm model: the first group is a blank test (none), the second group is vancomycin (Vancomycin, Van), daptomycin (Daptomycin, Dap) and Tosufloxacin (Tosufloxacin, Tosu) combination, the third group is the combination of Meropenem (Meropenem, Mer), Daptomycin (Daptomycin, Dap), Tosufloxacin (Tosufloxacin, Tosu) Medication, the fourth group is vancomycin (Vancomycin, Van), daptomycin (Daptomycin, Dap) and Clinafloxacin (Clinafloxacin, Clina) combined medication, the fifth group is meropenem (Meropenem, Mer), daptomycin Combination of Daptomycin (Dap) and Clinafloxacin (Clina). Through five groups of experiments, the results are as follows: figure 2 shown. in figure...
Embodiment 3
[0063] This example verifies that clinfloxacin has the best resistance activity among the anti-fluoroquinolones. In this example, the anti-biofilm activity of different fluoroquinolone antibiotics was ranked to determine whether the anti-biofilm activity of clinfloxacin used in the combined drug was unique to the drug itself, or could be replaced by other fluoroquinolone antibiotics. To test the idea, this example used the Newman's S. aureus strain, since this strain is susceptible to most fluoroquinolones, which would remove any confounding factors due to inherent resistance. For other fluoroquinolones, one of ciprofloxacin, levofloxacin, and moxifloxacin was combined with meropenem and daptomycin; after 4 days of combined medication, each drug combination produced certain anti-persistence or anti-biofilm active, and the combination with clinfloxacin is the most effective. In contrast, biofilms treated with other quinolones still contained 10 4 -10 8 CFU / ml (each millilite...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More